Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line

Boston, MA -- (SBWire) -- 10/14/2015 --Non-Small Cell Lung Cancer (NSCLC) is the second most common cancer globally, and the most common cause of cancer-related mortality. Such a poor outlook, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to complex treatment landscape based on different NSCLC subtypes and the presence of various molecular aberrations. In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapy. While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations.

Get More Details on this Report and a Full Table of Contents at Non-Small Cell Lung Cancer Therapeutics in Major Developed Markets to 2021 - Emergence of Immunotherapies Drives Market Growth and Creates A Competitive Second-Line

Scope

The NSCLC market will be valued at $10.9 billion in 2021, growing from $6.1 billion in 2014 at a CAGR of 8.5% -

-How will immunotherapies such as Keytruda affect growth?
-What effect will patent expirations of Tarceva and Alimta have on market value?

The NSCLC pipeline is large and diverse, with an increased presence of mAbs and specific targeted therapies in contrast to the market -

-What are the common targets and mechanisms of action of pipeline therapies?
-Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
-What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?

Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period -

-How have promising late-stage therapies performed in clinical trials?
-How would the approval of Rociletinib affect the competitive landscape?
-What is the individual commercial forecast for each therapy?

The market forecasts indicate that the US contributes the most to global market value due to a large treatment population and the high price of premium therapies.

-How will ACoT and market size vary between the eight major markets?
-How could a change in risk factors such as population age or smoking habits influence the market?

Licensing deals are the most common form of strategic alliance in NSCLC, with total deal values ranging from under $10m to over $1 billion.

-How do deal frequency and value compare between target families and molecule types?
-What were the terms and conditions of key licensing deals?

Reasons to Get This Report

This report will allow you to -

-Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
-Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs in the current market are highlighted to allow a competitive understanding of gaps in the current market.
-Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
-Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
-Predict NSCLC market growth in eight major markets with epidemiological and ACoT forecasts across the US, Canada, UK, France, Germany, Italy, Spain and Japan, as well as individual drug contributions to market growth.
-Identify commercial opportunities in the NSCLC deals landscape by analyzing trends in licensing and co-development deals.

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Global Lung Cancer Therapeutics Market 2015-2019
-Global Small Cell Lung Cancer Therapeutics Market 2015-2019
-Multiple Myeloma Therapeutics in Major Developed Markets to 2021 - Growth Driven by Rising Prevalence, Continued Success of Revlimid and Emerging Supplementary Treatments
-Non-Small Cell Lung Cancer - Pipeline Review, H1 2015
-Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth